» Articles » PMID: 2843547

Cell Surface Fibroblast Growth Factor and Epidermal Growth Factor Receptors Are Permanently Lost During Skeletal Muscle Terminal Differentiation in Culture

Overview
Journal J Cell Biol
Specialty Cell Biology
Date 1988 Aug 1
PMID 2843547
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

One characteristic of skeletal muscle differentiation is the conversion of proliferating cells to a population that is irreversibly postmitotic. This developmental change can be induced in vitro by depriving the cultures of specific mitogens such as fibroblast growth factor (FGF). Analysis of cell surface FGF receptor (FGFR) in several adult mouse muscle cell lines and epidermal growth factor receptor (EGFR) in mouse MM14 cells reveals a correlation between receptor loss and the acquisition of a postmitotic phenotype. Quiescent MM14 cells, mitogen-depleted, differentiation-defective MM14 cells, and differentiated BC3H1 muscle cells (a line that fails to become postmitotic upon differentiation) retained their cell surface FGFR. These results indicate that FGFR loss is not associated with either reversible cessation of muscle cell proliferation or biochemical differentiation and thus, further support a correlation between receptor loss and acquisition of a postmitotic phenotype. Comparison of the kinetics for growth factor receptor loss and for commitment of MM14 cells to a postmitotic phenotype reveals that FGFR rises transiently from approximately 700 receptors/cell to a maximum of approximately 2,000 receptors/cell 12 h after FGF removal, when at the same time, greater than 95% of the cells are postmitotic. FGFR levels then decline to undetectable levels by 24 h after FGF removal. During the interval in which FGFR increases and then disappears there is no change in its affinity for FGF. The transient increase in growth factor receptors appears to be due to a decrease in ligand-mediated internalization because EGFR, which undergoes an immediate decline when cultures are deprived of FGF (Lim, R. W., and S. D. Hauschka. 1984. J. Cell Biol. 98:739-747), exhibits a similar transient rise when cultures are grown in media containing both EGF and FGF before switching the cells to media without these added factors. These results indicate that the loss of certain growth factor receptors is a specific phenotype acquired during skeletal muscle differentiation, but they do not resolve whether regulation of FGFR number is causal for initiation of the postmitotic phenotype. A general model is presented in the discussion.

Citing Articles

A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer.

Okuneye K, Bergman D, Bloodworth J, Pearson A, Sweis R, Jackson T Comput Syst Oncol. 2022; 1(2).

PMID: 34984415 PMC: 8722426. DOI: 10.1002/cso2.1019.


Transdifferentiation of Human Fibroblasts into Skeletal Muscle Cells: Optimization and Assembly into Engineered Tissue Constructs through Biological Ligands.

Abdel-Raouf K, Rezgui R, Stefanini C, Teo J, Christoforou N Biology (Basel). 2021; 10(6).

PMID: 34208436 PMC: 8235639. DOI: 10.3390/biology10060539.


Upstream Regulator Analysis of Wooden Breast Myopathy Proteomics in Commercial Broilers and Comparison to Feed Efficiency Proteomics in Pedigree Male Broilers.

Bottje W, Lassiter K, Kuttappan V, Hudson N, Owens C, Abasht B Foods. 2021; 10(1).

PMID: 33419207 PMC: 7825620. DOI: 10.3390/foods10010104.


EGFR-Aurka Signaling Rescues Polarity and Regeneration Defects in Dystrophin-Deficient Muscle Stem Cells by Increasing Asymmetric Divisions.

Wang Y, Feige P, Brun C, Hekmatnejad B, Dumont N, Renaud J Cell Stem Cell. 2019; 24(3):419-432.e6.

PMID: 30713094 PMC: 6408300. DOI: 10.1016/j.stem.2019.01.002.


Effects of protease-treated royal jelly on muscle strength in elderly nursing home residents: A randomized, double-blind, placebo-controlled, dose-response study.

Meng G, Wang H, Pei Y, Li Y, Wu H, Song Y Sci Rep. 2017; 7(1):11416.

PMID: 28900247 PMC: 5595990. DOI: 10.1038/s41598-017-11415-6.


References
1.
Massague J, Cheifetz S, Endo T, Nadal-Ginard B . Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci U S A. 1986; 83(21):8206-10. PMC: 386896. DOI: 10.1073/pnas.83.21.8206. View

2.
Olwin B, Hauschka S . Identification of the fibroblast growth factor receptor of Swiss 3T3 cells and mouse skeletal muscle myoblasts. Biochemistry. 1986; 25(12):3487-92. DOI: 10.1021/bi00360a001. View

3.
Olson E, STERNBERG E, Hu J, Spizz G, Wilcox C . Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol. 1986; 103(5):1799-805. PMC: 2114366. DOI: 10.1083/jcb.103.5.1799. View

4.
Vlodavsky I, Folkman J, Sullivan R, Fridman R, Sasse J, Klagsbrun M . Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A. 1987; 84(8):2292-6. PMC: 304636. DOI: 10.1073/pnas.84.8.2292. View

5.
Baird A, Ling N . Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. Biochem Biophys Res Commun. 1987; 142(2):428-35. DOI: 10.1016/0006-291x(87)90292-0. View